Cost drivers of prescription opioid abuse in commercial and Medicare populations.
Pasquale, Margaret K; Joshi, Ashish V; Dufour, Robert; Schaaf, David; Mardekian, Jack; Andrews, George A; Patel, Nick C.
; 14(3): E116-25, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24268019
The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.
Differences in healthcare utilization and associated costs between patients prescribed vs. nonprescribed opioids during an inpatient or emergency department visit.
Empirical view of opioid dependence.
Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program.
Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
Economic burden of prescription opioid misuse and abuse.
Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
The economic burden of opioid-related poisoning in the United States.
Examining variation in treatment costs: a cost function for outpatient methadone treatment programs.